エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 20, 2024 |
PepGen Inc.
(Exact name of Registrant as Specified in Its Charter)
Delaware |
001-41374 |
85-3819886 |
||
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
321 Harrison Avenue 8th Floor |
|
|||
Boston, Massachusetts |
|
02118 |
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: (781) 797-0979 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
Common stock, par value $0.0001 per share |
|
PEPG |
|
Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On August 20, 2024, PepGen Inc. (the “Company”) announced the appointment of Paul Streck, M.D., MBA, as the Company’s Executive Vice President, Head of Research & Development. A copy of the press release issued in connection with this announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits:
Exhibit Number |
Description |
99.1 |
|
104 |
Cover Page Interactive Data Filed (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
PEPGEN INC. |
|
|
|
|
Date: |
August 20, 2024 |
By: |
/s/ Noel Donnelly |
|
|
|
Noel Donnelly, Chief Financial Officer |
PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development
BOSTON, August 20, 2024 -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointment of Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (R&D), effective immediately. Dr. Streck will join the PepGen Executive Team and will be responsible for leading the R&D organization.
“We are very pleased that Paul is joining PepGen at such an important time for the Company,” said James McArthur, Ph.D., President and CEO of PepGen. “Throughout his career, Paul has served in leadership roles across both large and small publicly traded biopharmaceutical companies, with notable accomplishments including five IND approvals, six global regulatory launches, and nine commercial product launches. This breadth of experience has equipped him with institutional knowledge that will be of extreme value to PepGen as we continue to advance our four active clinical trials and growing pipeline of preclinical candidates.”
Dr. Streck has more than 20 years of experience in drug development, regulatory, and medical affairs leadership. Most recently, he served as Chief Medical Officer at Albireo Pharma, a publicly traded rare disease biotechnology company acquired by Ipsen in March 2023. Previously, Dr. Streck was Chief Medical Officer at Arena Pharmaceuticals, a publicly traded immuno-inflammatory biotechnology company acquired by Pfizer in March 2022. Before that, he served as Chief Medical Officer at Alder Biopharmaceuticals, acquired by Lundbeck Pharmaceuticals in October 2020, and as the Chief Medical Officer of Insmed, advancing the company from clinical to commercial stage. Previous biopharmaceutical experience includes progressive roles at GSK, Shire, and Amgen, as well as 10 years in academic medical practice.
About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases.
For more information, please visit www.pepgen.com. Follow PepGen on LinkedIn and X.
Investor Contact
Dave Borah, CFA
SVP, Investor Relations and Corporate Communications
dborah@pepgen.com
Media Contact
Julia Deutsch
Lyra Strategic Advisory
Jdeutsch@lyraadvisory.com